Feedback
We’d love to hear your feedback on this activity. It helps us to continually improve our products.
CORRECT!
Faculty & Disclosures
Dr Matthew Lunning
University of Nebraska Medical Center, Omaha, NE, USA
Dr Matthew Lunning is an associate professor in the Division of Hematology/Oncology at the University of Nebraska Medical Center (UNMC) in Omaha, USA. He is also associate vice chair of research for the Department of Internal Medicine, assistant vice chancellor of Clinical Research, and medical director of gene and cellular therapies at the UNMC.read more
Dr Lunning was the recipient of the UNMC Distinguished Scientist Award in 2019. He has served on several National Comprehensive Cancer Network® guidelines committees, including the Management of Immunotherapy-Related Toxicity and T-Cell/Primary Cutaneous Lymphomas panels. He has also served as an invited member of the American Society of Clinical Oncology’s Cancer Education Committee on Non-Hodgkin Lymphoma and is the co-organizer of the Pan Pacific Lymphoma Conference.
Dr Matthew Lunning discloses: Consultancy fees from AbbVie, Acrotech Biopharma, ADC Therapeutics, AstraZeneca, Bristol Myers Squibb, Caribou Biosciences, CRISPR Therapeutics, Daiichi Sankyo, Fate Therapeutics, Genentech, Genmab, Incyte Corporation, Ipsen, Janssen Pharmaceuticals, Kite Pharma, Loxo Oncology, Nurix, Recordati, Regeneron Pharmaceuticals, Sanofi, Seagen and Vittoria Biotherapeutics. Grants/Research support from Bristol Myers Squibb, Fate Therapeutics and Sana Therapeutics.
Prof. Charalambos Andreadis
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA
Prof. Charalambos (Babis) Andreadis is a haematologist specializing in the treatment of lymphoma at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center in San Francisco, USA, where he leads the lymphoma programme. He is also the director of the Baszucki Lymphoma Therapeutic Initiative at UCSF.read more
He earned his medical degree at Columbia University’s Vagelos College of Physicians and Surgeons, then completed a residency at NewYork-Presbyterian Hospital and a fellowship in haematology and oncology at the Hospital of the University of Pennsylvania.
Prof. Andreadis’s research focuses on individualized therapies targeting disease subtypes, and immune effector cell therapies for haematological malignancies.
Prof. Charalambos Andreadis discloses: Advisory board or panel fees from AbbVie, AstraZeneca, Epizyme (an Ipsen company) and Gilead Sciences. Consultancy fees from Atara Biotherapeutics and Bristol Myers Squibb. Grants/Research support from Bristol Myers Squibb, Eli Lilly and Company, Genzyme, Merck, Novartis and Roche.
Dr Tara Graff
Mission Cancer and Blood, Des Moines, IA, USA
Dr Tara Graff is a medical oncologist and has worked at Mission Cancer and Blood in Des Moines, Iowa, USA for 10 years, specializing in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukaemia. She serves as the primary investigator for multiple clinical trials and is the physician director of the clinical trials programme for Mission Cancer and Blood.read more
Dr Graff serves on the BMS National CAR T-cell Advisory Board for Lymphoma, multiple national lymphoma advisory boards, the NHL Advisory Council and the LBCL (large B-cell lymphoma) Steering Committee. She is a member of the ECOG-ACRIN cancer research group, Lymphoma Working Committee for the Center for International Blood and Marrow Transplant Research and the Lymphoma Research Foundation. She is also the cellular therapy lead and co-chair of the Malignant Hematology Council for Exigent Research.
Dr Graff has published many original oncology and haematology articles and has paired with the Leukemia & Lymphoma Society to deliver education for patients with cancer in rural areas, and bispecific antibody and CAR T-cell therapy education for community oncologists.
Dr Tara Graff discloses: Advisory board or panel fees from AbbVie, Adaptive Biotechnologies, AstraZeneca, Bristol Myers Squibb, BeiGene, Eli Lilly and Company, Genmab and Kite Pharma. Consultancy fees from AbbVie, Genentech and Genmab. Speaker’s bureau fees from AbbVie, Adaptive Biotechnologies, ADC Therapeutics, AstraZeneca, BeiGene, Eli Lilly and Company, Genmab and Kite Pharma.
